New drug combo aims to slow stomach cancer progression
NCT ID NCT07432295
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 2 trial tests whether adding the experimental drug givastomig to standard immunotherapy and chemotherapy can help people with advanced stomach or esophageal cancer live longer without their cancer growing. About 180 adults whose tumors have certain proteins (CLDN18.2 and PD-L1) will receive either the new combo or standard treatment alone. Researchers will track side effects and how long the cancer stays under control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
givastomig (a targeted antibody) combined with nivolumab (immunotherapy) and chemotherapy
What this could lead to
If it works, this could point toward a more effective first-line treatment for people with advanced stomach or esophageal cancer that expresses certain proteins.
What could go wrong
This is an early Phase 2 trial with only 180 participants, so results may not apply to everyone. Adding a new drug also raises unknown side effect risks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
I-MAB Site 1005
RECRUITINGDuarte, California, 91010, United States
Contact
-
I-Mab Site - 4001
NOT_YET_RECRUITINGKashiwa, Japan
Contact
-
I-Mab Site 1002
RECRUITINGBoston, Massachusetts, 02114, United States
Contact
-
I-Mab Site 1016
RECRUITINGGoodyear, Arizona, 85338, United States
Contact
-
I-Mab Site 2001
RECRUITINGBeijing, China
Contact
-
I-Mab Site 4005
RECRUITINGTokyo, Japan
Contact